PMV Pharmaceuticals (PMVP)
(Delayed Data from NSDQ)
$1.58 USD
+0.02 (1.28%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $1.58 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PMVP 1.58 +0.02(1.28%)
Will PMVP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PMVP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PMVP
Here's Why You Should Consider Buying Bioventus (BVS) Stock
Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher
PMVP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock
PMV Pharmaceuticals, Inc. (PMVP) Loses -70.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Wall Street Analysts See a 239.26% Upside in PMV Pharmaceuticals, Inc. (PMVP): Can the Stock Really Move This High?
Other News for PMVP
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June
Buy Rating on PMV Pharmaceuticals: Strategic Partnerships and Promising Clinical Pipeline Underpin Positive Outlook
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
PMV Pharmaceuticals, Foundation Medicine announce collaboration